Treatment with an aromatase inhibitor improves outcomes at 10 years compared to treatment with a SERM in HR+, HER2+ early breast cancer.

SLNB can be safely omitted for patients with early-stage breast cancer patients who previously received breast-conserving surgery and whole-breast irradiation.

Patients with RRMM with renal impairment demonstrated similar efficacy and safety outcomes with talquetamab as those without renal impairment.

Receiving neoadjuvant endocrine therapy enabled many postmenopausal patients with ER+, HER2- breast cancer to undergo breast-conserving surgery.

Chronic immune-related adverse events occur in more than a third of patients with early-stage TNBC treated with pembrolizumab.

Researchers assessed survival outcomes for Asian patients with newly diagnosed AML vs White patients. Researchers determined Asian patients with newly diagnosed AML may have superior OS outcomes ...

Previous findings from the phase 3 DESTINY-Breast05 study (NCT04622319) showed that T-DXd demonstrated statistically significant and clinically meaningful improvement vs T-DM1 in the primary endpoint ...

Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.

Researchers sought to determine whether combination odronextamab plus CHOP would be safe and effective in patients with DLBCL. Combination odronextamab plus CHOP had promising response rates with a ...

Cancer Therapy Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...

In premenopausal women with non-metastatic breast cancer, use of tamoxifen may nearly double the risk of endometrial cancer, researchers report.

Adding tucatinib to first-line maintenance therapy with trastuzumab/pertuzumab extends PFS for patients with previously-treated HER2+ metastatic breast cancer.